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Abstract
Radiotherapy has an established role in the treatment of cancer and represents a defini-
tive, less invasive approach for various cancer types. Its main aim is to deliver the maxi-
mum dose to the tumor with minimal toxicity on neighboring healthy tissues. Therefore, 
the precise determination of the target and its spatial relation to critical surrounding 
organs is of main importance. New imaging modalities such as the CT, MRI, and PET/CT 
offer more anatomical detail and facilitate the accurate delineation of the target volume 
and the organs at risk. The recent advances in 3D-CRT and IMRT radiation techniques 
offer high accuracy in tumor targeting and ensure safe dose escalation. Moreover, the 
introduction of IGRT offers the opportunity to safely apply a supplementary dose to 
the macroscopic tumor. In trials conducted, a simultaneous integrated boost (SIB) has 
proved to be feasible in various cancer localizations, to safely increase the total delivered 
dose, shorten the total treatment time and results in increased tumor control while keep-
ing the side effects low at the same time. However, more trials need to be conducted to 
establish an acceptable protocol.
Keywords: radiation therapy, simultaneous integrated boost, fractionation, radiation 
dose escalation, image guided radiotherapy
1. Introduction
Radiation therapy is the core treatment strategy with curative intent and organ preservation for 
many inoperable cancer types. The main aim of radiation therapy is the local control of the tumor.
With open field conventional 2D RT, both healthy tissue and tumors are irradiated with a 
similar dose per fraction of 1.8–2 Gy. Now, the 3D-CRT is the new standardized procedure. 
The target volumes are defined on CT or PET-CT or other high-definition imaging such as 
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the MRI. During the treatment planning, a 3-D projection of the area of interest provides the 
opportunity to match the high-dose radiation region to the target volume while minimizing 
the radiation dose to the surrounding healthy tissue. More refined radiation techniques, which 
lead to enhanced conformity, can be performed with the use of these generation machines. 
3-D techniques have given way to IMRT or volumetric modulated arc therapy (V-MAT) [1–4].
High conformity is generally accepted as a way to reduce toxicity and allows dose escalation 
to produce better results and long-term tumor control. This is only possible through IGRT, 
which involves real-time imaging of the treatment target and normal organs during each 
treatment, in order to avoid uncertainty about patient positioning and tumor targeting and to 
also reduce the irradiated volumes without missing any of the targets [5].
Trials have investigated different fractionation schedules to also increase local control, which 
has become of high importance in clinical oncology patient management. Randomized clini-
cal trials have established equivalent outcomes between radical surgery and organ-preserva-
tion treatment with an RT backbone for appropriately selected patients.
The radiation oncologist's main concern is local recurrence after definitive radiation therapy. 
The combined chemo-radiation protocols have led to the increased tumor control and sur-
vival rates, but the results have remained unchanged for a long time. All eyes are now on 
radiation therapy for a more targeted improvement of local tumor control and diminishment 
of the odds of local recurrence [6].
The newly developed approach of applying different radiation doses to different areas in one 
single session is called SIB or simultaneous integrated boost-intensity-modulated radiotherapy 
(SIB-IMRT). By increasing the dose per fraction focally to the tumor itself while maintaining 
lower dose to the elective areas of interest, a more accurate dose distribution can be achieved, 
in order to improve local tumor control without putting the neighboring organs at risk. The 
advances, improvements and clinical usage of this technique will be expanded in full detail [7].
2. Simultaneous integrated boost–radiation therapy strategy and 
procedure
The radiation therapy strategy is an evidence-based treatment, personalized to the particular 
needs of each individual patient. The 3D-CRT is the minimum standard for the delivery of a 
radiation dose that conforms to the target volume and controls the exposure to surrounding 
tissue (Figure 1). The evolution of the 3D-CRT is the IMRT technique. It optimizes the radia-
tion intensity distribution within each beam in order to achieve a higher rate of conformity and 
target coverage especially for irregularly shaped tumors, using nonuniform radiation beam 
intensities to maximize the delivery of radiation to the planned target volume while minimiz-
ing irradiation of normal tissue outside the target. It requires a precise definition of anatomy, 
a treatment planning system that can calculate the dose in three dimensions, and a treatment 
device that can deliver the specified dose. Randomized studies demonstrate reduced side 
effects with IMRT (particularly that of xerostomia in patients with head and neck tumors) in 
comparison with older 3D-CRT techniques even in the setting of concurrent chemotherapy. 
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The delivery of each dose to the tumor has become much faster with the introduction of the 
VMAT where the gantry moves around the patient as the beam is being modulated (Figure 2). 
Typically, IMRT plans require 20–25 min for delivery of the daily treatment while a VMAT 
plan can now be delivered in approximately 3–5 min (approximately 1.5 min per gantry rota-
tional arc), which is easier on patients (Figure 3) [8–10].
Treatment planning is the most important procedure. Target delineation is the main concern 
of the radiation oncologist. The definition of the extension of the infiltrated tissue is often an 
interdisciplinary procedure where the surgeon, pathologist, radiologist and radiation oncologist 
have to collaborate in order to decide on the most appropriate treatment plan. The precise deter-
mination of the target and its spatial relation to critical surrounding organs is of main impor-
tance. The reference imaging modality for RT treatment planning is the CT with which we can 
Figure 1. 3D-CRT RT with multileaf collimator shielding.
Figure 2. IMRT: Gradient dose distribution is achieved in the different parts of the target volume, and the surrounding 
healthy tissue is less exposed to the total radiation dose.
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fuse additional medical images (MRI PET/CT scans) for accurate treatment planning, dosimetric 
calculations and ensure safe dose escalation. The PET/CT images can change gross tumor vol-
ume (GTV) delineation in 35–60% of patients treated and show a better treatment outcome (31 
months vs. 16 months) and can increase the 1-year survival rate from 8 to 17% (Figure 4) [11–15].
Figure 3. VMAT where the gantry moves around the patient as the beam is being modulated.
Figure 4. PET/CT gives information about the metabolic tumor activity.
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For accurate 3D-CRT and IMRT delivery, every day patient set up and verification systems are 
required, i.e., CBCT scanners, which produce 3-D images of the treatment area (Figure 5) [10, 11].
According to ICRU-83, the GTV represents the palpable or visible (on imaging) tumor, 
whereas the so-called clinical target volume (CTV) is an additional volume with a certain 
probability of microscopic (subclinical) malignant disease. The irradiated planning target vol-
ume (PTV) is a geometrical concept. The PTV is defined according to the ICRU 62 report and 
includes GTV, CTV and takes into account the internal organ motion and set up errors [16, 17].
In the past, radiation therapy was applied using a shrinking field approach or sequential boost, 
starting with large fields and shrinking gradually depending on the pre-planned total dose to 
each region. Inevitably, the high-risk target volume or GTV, the intermediate risk target vol-
ume or CTV and the low risk volume or PTV were exposed to different total doses, which have 
been delivered sequentially (SeqB-IMRT intensity-modulated radiotherapy sequential boost). 
This risk adaptive strategy now is modified to deliver a single efficient treatment plan with 
dose levels and intensities appropriate for each elected region. The SIB-IMRT is more confor-
mal and potentially enables a slightly higher dose escalation to high-risk volumes compared 
to the SeqB-IMRT. Higher conformity in combination with smaller PTV allows 25% RT dose 
escalation and increases the effectiveness of therapy. A dose escalation of 10 Gy to lung cancer 
patients treated with 3D-CRT is correlated with 36% decrease in local failure rates [18–20].
The concomitant boost technique is a variant of accelerated fractionation, whereby the boost 
is delivered as a second daily fraction during the basic treatment course to reduce the total 
duration of treatment. The incorporation of boost at the same session of RT is the SIB, which 
involves the CTV with a prophylactic dose and the GTV with a curative dose.
Figure 5. IGRT real-time imaging of the treatment area fused with the computer tomography image used for the 
planning.
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Simultaneous accelerated radiation therapy (SMART) boost technique initially was described 
by Butler in 1999 [21]. The GTV was treated with large fractions of 2.4 Gy, while conventional 
fractions of 2 Gy were delivered to the PTV, which represent the regions at risk for micro-
scopic disease up to a total dose of 60 and 50 Gy, respectively. The total treatment time was 
moderately shortened than previously. The term “simultaneous integrated boost” was intro-
duced later to define such treatment, delivering different doses per fraction in different target 
regions, by Mohan, 2000 [22]. The initial proposed dose delivery was either the conventional 
2 Gy per fraction to the lower or intermediate dose volumes, thereby enabling a higher dose 
per fraction to be delivered to the GTV, with as much as 2.4 Gy for gross disease. The SIB tech-
nique offers the biological advantage of shortened treatment duration, i.e., 70 Gy over 6 weeks, 
which has been shown to significantly increase the loco-regional control compared to the same 
dose delivered in 7 weeks. According to the literature provided, an increase in the biological 
dose of 7.5% could be translated into an increase in loco-regional control in the order of 15%. 
In this context, the gain resulting from an increase in the equivalent dose can be achieved with-
out any further increase in late normal tissue complications compared to standard treatment. 
Only the normal tissues embedded in the tumor volume and thus included in the PTV will be 
irradiated with a dose per fraction similar to that of the tumor itself. Provided that the dose 
per fraction to the organs at risk is limited to a maximum of 2 Gy per fraction, this increase in 
dose intensity will be achievable without undue damage to normal tissue (Figure 6) [23, 24].
In the following paragraphs, there are detailed examples of different cases where the SIB 
technique has been applied.
It is a fact that the treatment of head and neck cancers is influenced by fraction size, total dose 
and overall treatment time regarding the tumor control and toxicity. The total radiation dose 
has demonstrated a direct impact to the tumor response as well as to the acute or late adverse 
events.
The SIB-IMRT approach may be used to deliver a fraction size of 2.2 Gy to the boost volume 
and a fraction size of 1.8 Gy to the elective volume in the same treatment session. As a result, 
the high-risk volume is treated with fewer fractions compared to conventional protocols and 
leads to reduction in the overall treatment time (6 weeks compared to 7 weeks) (Figure 7).
Figure 6. SIB-IMRT gradient dose distribution in the different parts of the target volume and the surrounding healthy 
issue in one single session.
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According to the RTOG H-0022 trial for oropharyngeal carcinomas SIB-IMRT in head and 
neck cancer, the use of 2.0, 2.11 or 2.2 Gy per session is highly effective and safe with respect 
to tumor response and tolerance. However, SIB with 2.2 Gy is not recommended for large 
tumors involving laryngeal structures [25–32].
Before the arrival of IMRT, the SeqB method was mostly used, within the 3D conformal 
irradiation technique to treat high-grade gliomas. With the SIB method, the dose per frac-
tion to the PTV is lower when compared with the SEB, delivers an enhanced dose to the 
gross tumor volume and has a greater potential of sparing of organs at risk (Figure 8) 
[33–37].
Whole brain radiotherapy is the most common palliative treatment and has always been 
considered the standard treatment for patients with brain metastases. As opposed to sur-
gery which was used in the past decades, today neurosurgical techniques such as radio-
surgery have been combined with whole brain radiotherapy and have allowed for using 
more aggressive local treatment with the goal to increase local control probability and 
potentially overall survival. The literature reports a statistical advantage on overall sur-
vival probability in patients with a single brain metastasis treated with a combination 
of whole brain radiotherapy and radiosurgery compared with whole brain radiotherapy 
alone.
According to RTOG, the use of 20 Gy in five fractions to the WBRT can be considered an 
acceptable fractionation and is equivalent to 30 Gy in 2 weeks. Median survival (15–18 weeks) 
and overall response rates probability (75–80% for symptom palliation) are similar. The SIB 
together with this hypofractionated schedule in WBRT (20 Gy in five fractions) (40 Gy in 
five fractions) has proven to be feasible. This schedule offers the advantage of shorter treat-
ment time, which could be very useful in oligometastatic patients that need systemic therapy 
(Figure 9) [38–43].
Figure 7. Head and neck tumor, metabolic image activity for better targeting of GTV gross tumor volume.
Radiation Therapy with a Simultaneous Integrated Boost
http://dx.doi.org/10.5772/67326
129
Figure 8. CT after excision of a brain tumor, SIB-IMRT.
Figure 9. Single brain metastasis treated whole brain VMAT and SAB.
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The true value of radiotherapy confined to the thorax is indisputable in the treatment of 
locally advanced nonsmall cell lung cancer. However, even with standard chemo-radiation, 
it is difficult to achieve durable local control, and this contributes to the high morbidity and 
mortality of patients with NSCLC. Results of RTOG 0617 clinical (Phase III) trial showed that 
the overall survival of stage III NSCLC patients given a high-dose (74 Gy) conformal radiation 
therapy with concurrent chemotherapy was no better than that of patients given the standard 
dose (60 Gy) [44–46]. The new idea is, instead of escalating the dose to the whole PTV, to selec-
tively increase the treatment dose using SIB-IMRT to deliver a higher dose to the GTV and a 
relatively lower dose to the subclinical disease PTV [47–51].
Clinical outcomes of patients with NSCLC treated with SIB-IMRT have been retrospectively 
analyzed to evaluate the feasibility of this technology and to provide evidence in support of 
future clinical studies. The results so far should, at the very least, be considered encouraging 
(Figure 10).
Breast-conserving surgery followed by whole breast radiotherapy has become the standard 
approach for early stage breast cancer since the survival rates have proved to be similar to 
those with radical surgery. Local control can be improved by an additional boost of 16 Gy 
to the lumpectomy cavity after administration of 50 Gy to the whole breast. Breast irradia-
tion with a boost to the tumor bed provides significantly higher local recurrence rates than 
whole breast irradiation alone, namely, 93.8% vs. 89.8% at 10 years. In the EORTC study 
22881–10882, the absolute benefit of a boost in terms of local control was most pronounced in 
young patients [52–55].
A new technical perspective is to apply SIB to the whole breast 3D-CRT plan, in one integrated 
treatment schedule throughout the entire course of treatment. In this case, the whole breast 
represents the PTV and is exposed to a daily fraction of 1.8 Gy for 28 days, a total dose of 50, 
Figure 10. SIB treatment plan in lung cancer nodal recurrence.
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40 Gy. Additionally, the tumor bed CTV is delineated, guided by the presence of the surgical 
clips, hematoma, seroma and/or other surgery-induced changes and is irradiated with a daily 
dose of 2.3 Gy (76.2%) or 2.4 Gy (23.8%) adding up to a total dose of 64.4 Gy or 67.2 Gy. These 
fractionation schemes are biologically equivalent to the sequential boost technique [56, 57].
The SIB technique is proposed for standard use in breast-conserving radiation therapy, because 
it can be easily implemented to reduce excess volumes of normal tissue irradiated, shorten the 
treatment course, decrease the dose per fraction for the breast, and increase the dose per frac-
tion for the boost, with a relatively low incidence of acute skin toxicity (Figure 11).
The prospective RTOG 0529 phase II trial investigated the utility of IMRT in anal cancer. The two-
year loco-regional control rate was 80%. In comparison with the results of RTOG 98–11, the use of 
IMRT reduced early G3 or higher gastrointestinal toxicity from 36 to 22%, and G3 or higher skin 
toxicity from 47 to 20%. However, until long-term control rates become available, concerns remain 
regarding potential compromise of tumor control rates using more conformal radiotherapy.
Several different SIB-IMRT schedules are described in various literatures. In the RTOG trial, 
the total dose varied according to T stage, in which 45 Gy/50.4 Gy was given to T1/T2 and 
55–59 Gy/54 Gy to T3/4 tumors (RTOG 98–11, RTOG 0529). In contrast to tactics used in many 
US centers, where 59 Gy were administered regardless of T stage, with very few exceptions 
for very small primary tumors [58–62].
A new SIB-IMRT schedule is presented to treat patients with anal cancer in two series using 
moderate single doses from 1.5 to 2.0 Gy with a total dose of 59 Gy in combination with 
 Figure 11. SIB breast cancer-tumor bed guided by the presence of the surgical clips.
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mitomycin and 5FU 5FU/MMC. The results, in terms of loco-regional control and toxicity, are 
comparable to the results of other studies. Remarkably, the incidence of treatment interrup-
tions was very low. Therefore, this regimen appears to be safe and favorable for clinical use.
The optimal technique of IMRT with or without SIB is still under debate, and up to date no 
standard SIB-IMRT schedule has been established.
The overall radiation therapy treatment time plays an important role, since every single one 
day prolongation of treatment beyond 30 days leads to 1% loss of tumor control in patients 
with cervix carcinoma. The presence of lymph node metastases in cervical cancer patients is a 
significant risk factor for disease recurrence. Currently available data showed that 18FDG-PET\
CT detects more favorable results as far as regional disease when compared with the CT or 
MRI. PET/CT contributes to better disease control as far as better diagnosis of local and regional 
disease spread with consequent better delineation based on molecular data [63–66].
IMRT with simultaneous integrated boost (SIB) improves the therapeutic ratio and delivers 
different doses to different parts of the irradiated volume through dose painting. Further tri-
als are needed in order to optimize the treatment procedure (Figure 12).
Local recurrences after external beam radiotherapy for prostate cancer are dose-dependent 
and mainly occur in the dominant intraprostatic lesion, i.e., the initial tumor site. Trials pub-
lished demonstrated the feasibility and safety of delivering a SIB to the dominant intrapros-
tatic lesion. No increase in acute and late GU or rectal toxicity was observed when performing 
a SIB up to an eight-year follow-up. The impact on outcome of focal boosting to the dominant 
Figure 12. Follow-up of a patient treated with SIB-IMRT.
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intraprostatic lesion is currently evaluated in an ongoing phase 3 trial randomizing interme-
diate and high-risk prostate cancer patients to receive either 77 Gy (35 fractions) or 77 Gy to 
the prostate with an additional boost to the macroscopic tumor up to 95 Gy [67–71].
3. Conclusion
The SIB-IMRT or SMART is feasible and time sparing with encouraging loco-regional results 
and controlled side effects. From a radiobiological point of view, it appears to be an effective 
RT strategy for the primary treatment of H&N cancers, and also for various other cancer types. 
Many different SIB schedules have been employed so far, but a standard regimen has not yet 
been defined. Based on the available published studies on the SIB-IMRT, the short-term clinical 
outcome is very promising. However, very few data on late effects are available as of yet, due 
to the short follow-up time in the majority of the reported studies. However, further data are 
awaited shortly from ongoing clinical trials in order to determine the most efficient protocol.
For the past 5 years, our department has been using the SIB method where it is applicable. All 
images shown in this chapter are actual images of patients we personally have treated.
Acknowledgements
To our medical physicist, radiologist and nurses without whose assistance none of this would 
have been possible. We are privileged to have our devoted, attentive, not to mention excel-
lently trained personnel as well as the state-of-the-art technological equipment our facilities 
have to offer, at our disposal.
Conflicts of interest statement
Nothing to declare.
Author details
Despina Katsochi
Address all correspondence to: dkatsochi@aktinotherapeia.com
Hygeia Hospital, Athens, Greece
References
[1] Brahme A. Design principles and clinical possibilities with a new generation of radiation 
therapy equipment. A review. Acta Oncol. 1987;26:403.
Radiotherapy134
[2] Bortfeld T, Bürkelbach J, Boesecke R, Schlegel W. Methods of image reconstruction from 
projections applied to conformation radiotherapy. Phys Med Biol. 1990;35:1423.
[3] Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: 
Part I. Br J Radiol. 2004;77:88. DOI:10.1259/bjr/54028034
[4] Scorsetti M, Fogliata A, Castiglioni S. Early clinical experience with volumetric 
modulated arc therapy in head and neck cancer patients. Radiat Oncol. 2010;5:93. 
DOI:10.1186/1748-717X-5-93
[5] Stützel J, Oelfke U, Nill S. Linac integrated kV-cone beam CT: Technical features and first 
applications. Med Dosim. 2006;31:62–70. DOI:10.1016/j.meddos.2005.12.008
[6] Dandekar V, Morgan T, Turian J. Patterns-of-failure after helical tomotherapy-based 
chemoradiotherapy for head and neck cancer: Implications for CTV margin, elective 
nodal dose and bilateral parotid sparing. Oral Oncol. 2014;50:520–526. DOI:10.1016/j.
oraloncology.2014.02.009
[7] Lauve A, Morris M, Schmidt-Ullrich R. Simultaneous integrated boost intensity-mod-
ulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: 
II-clinical results. Int J Radiat Oncol Biol Phys. 2004;60:374–387.
[8] Bourhis J, Overgaard J, Audry H. Hyperfractionated or accelerated radiotherapy in head 
and neck cancer: A meta-analysis. Lancet. 2006;368:843. DOI:10.1016/S0140-6736(06)69121-6
[9] Marks LB, Yorke ED, Jackson A. Use of normal tissue complication probability mod-
els in the clinic. Int J Radiat Oncol Biol Phys. 2010;376:S10–S976. DOI:10.1016/j.
ijrobp.2009.07.1754
[10] Schäfer M, Münter M, Sterzing F, Häring P, Rhein B, Debus J. Measurements of char-
acteristics of time pattern in dose delivery in step-and-shoot IMRT. Strahlenther Onkol. 
2005;181:587. DOI:10.1007/s00066-005-1289-7
[11] Grégoire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment plan-
ning in radiotherapy: A new standard? J Nucl Med. 2007;48:68S–77S.
[12] Garden AS, Morrison WH, Wong PF, Tung SS, Rosenthal DI, Dong L, Mason B, Perkins 
GH, Ang KK. Disease-control rates following intensity-modulated radiation therapy 
for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67:438. 
DOI:10.1016/j.ijrobp.2006.08.078
[13] Morin O, Gillis A, Chen J, Aubin M, Bucci K, Roach M, Pouliot J. Megavoltage cone-
beam CT: System description and clinical applications. Med Dosim. 2006;31:51–61. 
DOI:10.1016/j.meddos.2005.12.009
[14] Mac Manus M, Hicks RJ, Everitt S. Role of PET-CT in the optimization of thoracic radio-
therapy. J Thorac Oncol. 2006;1(1):81–84. DOI:org/10.1016/S1556-0864(15)31519-7
[15] Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, Matthews JP, Ball 
DL. PET provides high-impact and powerful prognostic stratification in staging newly 
diagnosed non-small cell lung cancer. J Nucl Med. 2001 Nov;42(11):1596-604
Radiation Therapy with a Simultaneous Integrated Boost
http://dx.doi.org/10.5772/67326
135
[16] Menzel HG. The International   Commission on Radiation Units and Measu r ements   
(ICRU), since its inception in 1925, has had as its principal. J ICRU. 2010;10:83. DOI:10. 
1016/j.ijrobp. 2009.07.1754
[17] Marks LB, Yorke ED, Jackson A. Use of normal tissue complication probability models in 
the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–S19. DOI:10.1016/j.ijrobp.2004.04.013
[18] Rengan R, Rosenzweig KE, Venkatraman E, Koutcher LA, Fox JL, Nayak R, Amols H, 
Yorke E, Jackson A, Ling CC, Leibel SA. Improved local control with higher doses of 
radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol 
Phys. 2004;60(3):741–747.
[19] Dogan N, King S, Emami B, Mohideen N, Mirkovic N, Leybovich LB, Sethi A. Assessment 
of different IMRT boost delivery methods on target coverage and normal-tissue sparing. 
Int J Radiat Oncol Biol Phys. 2003;57:1480–1491.
[20] Fu KK, Pajak TF, Trotti A. A Radiation Therapy Oncology Group (RTOG) phase III 
randomized study to compare hyperfractionation and two variants of accelerated frac-
tionation to standard fractionation radiotherapy for head and neck squamous cell carci-
nomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7. DOI:10.1016/j.
ijrobp.2004.03.010
[21] Butler EB, Teh BS, Grant WH, Woo S. Smart (simultaneous modulated accelerated radia-
tion therapy) boost: a new accelerated fractionation schedule for the treatment of head 
and neck cancer with intensity modulated radiotherapy – What is the price for speed-
ing? Int J Rad Oncol Biol Phy. 1999;45(1):21–32. DOI: 10.1016/S1470-2045(11)70346-1
[22] Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the 
design of fractionation strategies for intensity-modulated radiation therapy of head and 
neck cancers. Int J Radiat Oncol Biol Phys. 2000;46:619.
[23] Bourhis J, Sire C, Graff P. Concomitant chemoradiotherapy versus acceleration of radio-
therapy with or without concomitant chemotherapy in locally advanced head and neck 
carcinoma (GORTEC 99–02): An open-label phase 3 randomised trial. Lancet Oncol. 
2012;13:145.
[24] Denis F, Garaud P, Bardet E. Final results of the 94–01 French Head and Neck Oncology 
and Radiotherapy Group randomized trial comparing radiotherapy alone with con-
comitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 
2004;22:69.
[25] Marcial VA, Pajak TF, Chang C. Hyperfractionated photon radiation therapy in the 
treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and 
sinuses, using radiation therapy as the only planned modality: (preliminary report) by 
the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys. 1987;13:41.
[26] Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H. Hyperfractionation: 
Where do we stand? Radiother Oncol. 1997;43:1.
Radiotherapy136
[27] Eisbruch A, Harris J, Garden AS. Multi-institutional trial of accelerated hypofractionated 
intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 
00–22). Int J Radiat Oncol Biol Phys. 2010;76:1333–1338. DOI:10.1016/j.ijrobp.2009.04.011
[28] Songthong AP, Kannarunimit D, Chakkabat C. A randomized phase II/III study of adverse 
events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity 
modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result 
on acute adverse events. Radiat Oncol. 2015;10:166. DOI:10.1186/s13014-015-0472-y
[29] Koom WS, Kim TH, Shin KH, Pyo HR, Kim JY, Kim DY, Yoon M, Park SY, Lee DH, Ryu JS, 
Jung YS, Lee SH, Cho KH. Smart (Simultaneous Modulated Accelerated Radiotherapy) 
for locally advanced nasopharyngeal carcinomas. Head Neck. 2008;10:159–169. DOI:10. 
1002/hed.20667
[30] Nguyen-Tan PF, Zhang Q, Ang KK. Randomized phase III trial to test accelerated versus 
standard fractionation in combination with concurrent cisplatin for head and neck carci-
nomas in the Radiation Therapy Oncology Group 0129 trial: Long-term report of efficacy 
and toxicity. J Clin Oncol. 2014;32:3858. DOI:10.1200/JCO.2014.55.3925
[31] Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, 
Harris J, Ang KK. Final results of local-regional control and late toxicity of rtog 9003: A 
randomized trial of altered fractionation radiation for locally advanced head and neck 
cancer. Int J Radiat Oncol Biol Phys. 2014;89:13–20. DOI:10.1016/j.ijrobp.2013.12.027
[32] Xiao C, Hanlon A, Zhang Q. Risk factors for clinician-reported symptom clusters in 
patients with advanced head and neck cancer in a phase 3 randomized clinical trial: 
RTOG 0129. Cancer. 2014;120:848. DOI:10.1002/cncr.28500
[33] Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ. Radiotherapy 
plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352: 
987–996. DOI:10.1056/NEJMoa043330
[34] Farzin M, Molls M, Astner S, Rondak IC, Oechsner M. Simultaneous integrated vs. 
sequential boost in VMAT radiotherapy of high-grade gliomas. Strahlenther Onkol. 
2015;191:945–952. DOI: 10.1056/NEJMoa043330
[35] Sultanem K, Patrocinio H, Lambert C, Corns R, Leblanc R, Parker W. The use of hypofrac-
tionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: 
Preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys. 2004;58:247–252.
[36] Monjazeb AM, Ayala D, Jensen C, Case LD, Bourland JD, Ellis TL. A phase I dose esca-
lation study of hypofractionated IMRT field-in-field boost for newly diagnosed glio-
blastoma multiforme. Int J Radiat Oncol Biol Phys. 2012;82:743–748. DOI:10.1016/j.
ijrobp.2010.10.018
[37] Truc G, Bernier V, Mirjolet C, Dalban C, Mazoyer F, Bonnetain F, Blanchard N, Lagneau 
É, Maingon P, Noël G. A phase I dose escalation study using simultaneous integrated-
boost IMRT with temozolomide in patients with unifocal glioblastoma. Cancer/
Radiothérapie. 2016:20;193–198. DOI:10.1016/j.canrad.2015.12.005
Radiation Therapy with a Simultaneous Integrated Boost
http://dx.doi.org/10.5772/67326
137
[38] Giaj N, Gianluisa L, Alba S, Sergio F, Ricchetti F, Mazzola R, Naccarato S, Ruggieri R, 
Filippo A. Whole brain radiotherapy with hippocampal avoidance and simultaneous 
integrated boost for brain metastases: A dosimetric volumetric-modulated arc therapy 
study. Radiol Med. 2016;121:60–69. DOI:10.1007/s11547-015-0563-8.
[39] Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers 
CL, Souhami L. The American society for therapeutic radiology and oncology (ASTRO) 
evidence based review of the role of radiosurgery for brain metastasis. Int J Radiat Oncol 
Biol Phys. 2005;63:37–46. DOI:10.1016/j.ijrobp.2005.05.023.
[40] Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosur-
gery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple 
brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427–434.
[41] Andrews DW, Scott CB, Sperduto PW. Whole-brain radiation therapy with or without 
stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III 
results of the RTOG-9508 randomized trial. Lancet. 2004;363:1665–1672. DOI:10.1016/
S0140-6736(04)16250-8
[42] Prokic V, Wiedenmann N, Fels F, Schmucker M, Nieder C, Grosu AL. Whole brain irra-
diation with hippocampal sparing and dose escalation on multiple brain metastases: A 
planning study on treatment concepts. Int J Radiat Oncol Biol Phys. 2013;85:264–270. 
DOI:10.1016/j.ijrobp.2012.02.036
[43] Lagerwaard FJ, van der Hoorn EA, Verbakel WF, Haasbeek CJ, Slotman BJ, Senan S. 
Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metas-
tases using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys. 2009;75:253–
259. DOI:10.1016/j.ijrobp.2009.03.029
[44] Barraclough LH, Swindell R, Livsey JE, Hunter RD, Davidson SE. External beam boost 
for cancer of the cervix uteri when intracavitary therapy cannot be performed. Int J 
Radiat Oncol Biol Phys. 2008;71:772–778. DOI:10.1016/j.ijrobp.2007.10.066
[45] Van de Bunt L, Jurgenliemk-Schulz IM, de Kort GA, Roesink JM, Tersteeg RJ, van der Heide 
UA. Motion and deformation of the target volumes during IMRT for cervical cancer: What 
margins do we need? Radiother Oncol. 2008;88:233–240. DOI:10.1016/j.radonc.2007.12.017
[46] Kaatee RS, Olofsen MJ, Verstraate MB, Quint S, Heijmen BJ: Detection of organ move-
ment in cervix cancer patients using a fluoroscopic electronic portal imaging device and 
radiopaque markers. Int J Radiat Oncol Biol Phys. 2002;54:576–583.
[47] Van Baardwijk A, Wanders S, Boersma L. Mature results of an individualized radiation 
dose prescription study based on normal tissue constraints in stages I to III non-small-
cell lung cancer. J Clin Oncol. 2010;28:1380–1386. DOI:10.1200/JCO.2009.24.7221
[48] Bradley JD, Paulus R, Komaki R. Standard-dose versus high-dose conformal radio-
therapy with concurrent and consolidation carboplatin plus paclitaxel with or without 
cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A 
randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–199.
Radiotherapy138
[49] Vera P, Bohn P, Edet-Sanson A. Simultaneous positron emission tomography (PET) 
assessment of metabolism with (18)F-fluoro-2-deoxy-d-glucose (FDG), proliferation 
with (18)F-fluoro-thymidine (FLT), and hypoxia with (18)fluoro-misonidazole (F-miso) 
before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): A 
pilot study. Radiother Oncol. 2011;98:109–116. DOI:10.1016/j.radonc.2010.10.011
[50] Even AJG, van der Stoep J, Zegers CML, Reymen B, Troost EGC, Lambin P, van Elmpt 
W. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose 
escalation with boosting hypoxic and metabolically active sub-volumes. Radiother 
Oncol. 2015;116(2):281–286. DOI:10.1016/j.radonc.2015.07.013.
[51] Han D, Qin Q, Hao S, Huang W, Wei Y, Zhang Z, Wang Z, Li B. Feasibility and effi-
cacy of simultaneous integrated boost intensity-modulated radiation therapy in patients 
with limited-disease small cell lung cancer. Radiat Oncol. 2014;11(9):280. DOI:10.1186/
s13014-014-0280-9.
[52] Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A. 
Impact of a higher radiation dose on local control and survival in breast-conserving ther-
apy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 
22881–10882 trial. J Clin Oncol. 2007;25:3259–3265. DOI:10.1200/JCO.2007.11.4991.
[53] Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM. The UK 
Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofraction-
ation for treatment of early breast cancer: A randomised trial. Lancet Oncol. 2008;9:331–
341. DOI:10.1016/S1470-2045(08)70077-9
[54] Dellas K, Vonthein R, Zimmer J, Dinges S, Boicev AD, Andreas P. Hypofractionation 
with simultaneous integrated boost for early breast cancer: Results of the German multi-
center phase II trial (ARO-2010-01). Strahlenther Onkol. 2014;190:646–653. DOI:10.1007/
s00066-014-0658-5
[55] Sedlmayer F, Sautter-Bihl ML, Budach W, Dunst J, Fastner G, Feyer P. DEGRO practical 
guidelines: Radiotherapy of breast cancer I: Radiotherapy following breast conserving 
therapy for invasive breast cancer. Strahlenther Onkol. 2013;189:825–833. DOI:10.1007/
s00066-013-0437-8
[56] Alford SL, Prassas GN, Vogelesang CR, Leggett HJ, Hamilton CS. Adjuvant breast radio-
therapy using a simultaneous integrated boost: Clinical and dosimetric perspectives. J 
Med Imaging Radiat Oncol. 2013;57:222–229. DOI:10.1111/j.1754-9485.2012.02473.x
[57] Bantema-Joppe EJ, Schilstra C, de Bock GH, Dolsma WV, Busz DM, Langendijk JA. 
Simultaneous integrated boost irradiation after breast-conserving surgery: Physician-
rated toxicity and cosmetic outcome at 30 months' follow-up. Int J Radiat Oncol Biol 
Phys. 2012;83:e471–e477. DOI:10.1016/j.ijrobp.2012.01.050
[58] Hsu A, Hara W, Pawlicki J. IMRT in the treatment of anal cancer: A dosimetric com-
parison of conventional 3D, IMRT, and IMRT with integrated boost. Proc Am Soc Ther 
Radiol Oncol. 2006;66:674.
Radiation Therapy with a Simultaneous Integrated Boost
http://dx.doi.org/10.5772/67326
139
[59] Ajani JA, Winter KA, Gunderson LL. Intergroup RTOG 98–11: A phase III random-
ized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluoroura-
cil, cisplatin and radiotherapy in carcinoma of the anal canal. Proc Am Soc Clin Oncol. 
2012;26:18. DOI:10.1200/JCO.2012.43.8085
[60] Chen YJ, Liu A, Tsai PT, Vora NL, Pezner RD, Schultheiss TE, Wong JY. Organ sparing by 
conformal avoidance intensity-modulated radiation therapy for anal cancer: Dosimetric 
evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol 
Phys. 2005;63:274–281. DOI:10.1016/j.ijrobp.2005.05.052
[61] Kachnic LA1, Winter K, Myerson RJ, Goodyear MD, Willins J. Esthappan J, Haddock 
MG, Rotman M, Parikh PJ, Safran H, Willett CG. Radiation Therapy Oncology Group 
(RTOG). A Phase II Evaluation of Dose-Painted IMRT in Combination with 5-Fluorouracil 
and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal, 
RTOG 05-29. RTOG, Philadelphia, PA. 2012. Int J Radiat Oncol Biol Phys. 2013 May 
1;86(1):27–33. DOI:10.1016/j.ijrobp.2012.09.023
[62] Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ, Milano MT. Intensity-modulated 
radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. 
Int J Radiat Oncol Biol Phys. 2005;63:354–361. DOI:10.1016/j.ijrobp.2005.02.030
[63] Georg D, Kirisits C, Hillbrand M, Dimopoulos J, Potter R. Image-guided radiotherapy 
for cervix cancer: High-tech external beam therapy versus high-tech brachytherapy. Int J 
Radiat Oncol Biol Phys. 2008;71:1272–1278. DOI:10.1016/j.ijrobp.2008.03.032
[64] Lim K, Small W Jr, Portelance L, Creutzberg C, Jurgenliemk-Schulz IM, Mundt A, Mell 
LK, Mayr N, Viswanathan A, Jhingran A. Consensus guidelines for delineation of clini-
cal target volume for intensity-modulated pelvic radiotherapy for the definitive treat-
ment of cervix cancer. Int J Radiat Oncol Biol Phys. 2011;79:348–355. DOI:10.1016/j.
ijrobp.2009.10.075
[65] Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control 
of cervix cancer. Radiother Oncol. 1992;25:273–279.
[66] Molla M, Escude L, Mouet P, Popowski Y, Hidalgo A, Rouzaud M, Linero D, Miralbell 
R. Fractionated stereotactic radiotherapy boost for gynecologic tumors: An alternative 
to brachytherapy? Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):118–24. DOI:10.1016/j.
ijrobp. 2004.09.028
[67] Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B. Dose escalation for 
prostate cancer radiotherapy: Predictors of long-term biochemical tumor control and 
distant metastases-free survival outcomes. Eur Urol. 2011;60:1133–1139. DOI:10.1016/j.
eururo.2011.08.029
[68] Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N. Intensity-
modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxic-
ity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J 
Radiat Oncol Biol Phys. 2008;72:799–807. DOI:10.1016/j.ijrobp.2008.01.040
Radiotherapy140
[69] Ippolito E, Mantini G, Morganti AG, Mazzeo E, Padula GD, Digesu C. Intensity-
modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic 
lesion: Preliminary report on toxicity. Am J Clin Oncol. 2012;35:158–162. DOI:10.1097/
COC.0b013e318209cd8f
[70] Lips IM, van der Heide UA, Haustermans K, van Lin EN, Pos F, Franken SP. Single 
blind randomized phase III trial to investigate the benefit of a focal lesion ablative micro-
boost in prostate cancer (FLAME-trial): Study protocol for a randomized controlled trial. 
Trials. 2011;12:255. DOI:10.1186/1745-6215-12-255
[71] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group 
(RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). 
Int Radiat Oncol Biol Phys. 1995;31:1341–1346. DOI:10.1016/0360-3016(95)00060-C.
Radiation Therapy with a Simultaneous Integrated Boost
http://dx.doi.org/10.5772/67326
141

